Showing 2,021 - 2,040 results of 47,188 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((wt decrease) OR (mean decrease)) ))', query time: 0.72s Refine Results
  1. 2021

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  2. 2022

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  3. 2023
  4. 2024

    The effects of TDBP-TAZTO (5 and 50 mg/kg) on spatial learning and memory in rats in the Morris water test. by Liang Ye (6646)

    Published 2015
    “…Data ate expressed as mean ± SE (n = 10/group). <sup>a</sup><i>p</i> < 0.05, TDBP-TAZTO 5 mg/kg group vs. control group; <sup>b</sup><i>p</i> < 0.05, TDBP-TAZTO 50 mg/kg group vs. control group.…”
  5. 2025
  6. 2026
  7. 2027
  8. 2028
  9. 2029
  10. 2030
  11. 2031

    Effects of siRNA TMPRSS2-ERG on ERG protein expression and cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<p>VCaP cells were transfected for 24h, 48h and 72h with 50 nM of siRNAs TMPRSS2-ERG III (1, 2, 3), siRNAs TMPRSS2-ERG IV (1, 2), siRNA against ERG wild type or siRNA Control. …”
  12. 2032
  13. 2033
  14. 2034
  15. 2035

    Datasheet1_Acquired von Willebrand syndrome (AVWS) type 2, characterized by decreased high molecular weight multimers, is common in children with severe pulmonary hypertension (PH)... by Ivonne Wieland (14112981)

    Published 2022
    “…Hemostatic complications were observed in 4 of 12 (33%) patients with VWS and 3 of 6 (50%) patients without diagnostics and therapy.</p>Conclusion<p>For children with moderate to severe PH, we recommend systematic analysis of von Willebrand variables, including multimer analysis, PFA-100 and platelet function testing. …”
  16. 2036
  17. 2037

    BRET<sup>2</sup> measurement of Gα<sub>q</sub>β<sub>1</sub>γ<sub>2</sub> complex activation in HEK293 living cells expressing equal amounts of the WT of human TP receptor or its E1... by Valérie Capra (396007)

    Published 2013
    “…Agonist-induced coupling of TP receptor and Gq protein distances Gα<sub>q</sub>-Rluc8 and GFP<sup>10</sup>-Gγ<sub>2</sub> giving rise to a decrease in the BRET signal. B. Protein expression levels of the constructs used for BRET experiments were set to be constant and able to assure the same level of basal BRET ratio in the presence of WT and E129V mutant of the human TP receptors. …”
  18. 2038
  19. 2039
  20. 2040